Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630041 | 1.00 | CYP3A4 (0.33) | CYP3A4ALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL629678 | 0.82 | CYP3A4 (0.40) | CYP3A4ALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL16094286 | 0.75 | CYP3A4 (0.30) | CYP3A4GRIN2B | |
| SCHEMBL16098780 | 0.73 | ALDH1A1 (0.31) | CYP3A4ALDH1A1GRIN2B | |
| SCHEMBL3173563 | 0.73 | ALDH1A1 (0.31) | CYP3A4ALDH1A1GRIN2B | |
| SCHEMBL16099547 | 0.73 | ALDH1A1 (0.31) | CYP3A4ALDH1A1GRIN2B | |
| SCHEMBL19996049 | 0.73 | — | — | |
| SCHEMBL16094012 | 0.71 | CYP3A4 (0.31) | CYP3A4GRIN2B | |
| SCHEMBL9094219 | 0.71 | GRIN2B (0.31) | GRIN2B | |
| SCHEMBL9222201 | 0.69 | ALDH1A1 (0.30) | CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165578-B1 | METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS | PRIEBE WALDEMAR (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7557090-B2 | Anthracycline antibiotics and methods of treating cancer using the same | HOUSTON PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070037758-A1 | administering with a DNA damaging agent; modified alkyl-aromatic ring substitutions on the C-3' of the sugar moiety or alkyl-aromatic ring substitutions at the C-4' of the sugar; cytotoxicity; antitumor, anticarcinogenic agents; multidrug resistance; compounds act by intercalating with DNA | HOUSTON PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-7109177-B2 | Methods and compositions for the manufacture of C-3′ and C-4′ anthracycline antibiotics | HOUSTON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050004048-A1 | Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-06 | — | — | US | disclosed |
| US-6673907-B2 | NOVEL SUBSTITUTED TETRACYCLINES WITH MODIFIED ALKYL-AROMATIC RING SUBSTITUTIONS ON THE C-3' AND/OR C-4' OF THE SUGAR MOIETY; CYTOTOXICITY; ANTITUMOR, -CARCINOGENIC AGENTS; MULTIDRUG RESISTANCE | HOUSTON PHARMACEUTICALS, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20020137694-A1 | Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-26 | — | — | US | disclosed |
| EP-1165578-A4 | METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS | PRIEBE WALDEMAR (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1165578-A2 | METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS | Priebe, Waldemar (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056267-A2 | METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS | PRIEBE WALDEMAR (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004048-A1 | Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics | HCCS, ABCC3, MYC | CYP3A4 202/4885ALDH1A1 2070/4885MEN1 1829/4885 |
| US-20070037758-A1 | administering with a DNA damaging agent; modified alkyl-aromatic ring substitutions on the C-3' of the sugar moiety or alkyl-aromatic ring substitutions at the C-4' of the sugar; cytotoxicity; antitumor, anticarcinogenic agents; multidrug resistance; compounds act by intercalating with DNA | PCNA, DDB1, TOP1 | CYP3A4 1124/4885ALDH1A1 1945/4885MEN1 4030/4885 |
| US-20020137694-A1 | Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics | HCCS, GALE, BCL3 | CYP3A4 126/4885ALDH1A1 2453/4885MEN1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.